| 2022 | 2021 | ||||
|---|---|---|---|---|---|
| Unrestricted | Total | ||||
| fund | funds | ||||
| Notes | E | f | |||
| INCOME AND ENDOWMENTS | FROM | ||||
| Investment income |
26,722 | 25,165 | |||
| EXPENDITURE ON | |||||
| Charitable activities | |||||
| General donations to other charitable | |||||
| causes | 13,190 | 38,000 | |||
| Other | 2,309 | 930 | |||
| Total | 15,499 | 38,930 | |||
| Net gains on investments | 7,068 | 215,450 | |||
| NET INCOME | 18,291 | 201,685 | |||
| RECONCILIATION | OF FUNDS | ||||
| Total funds brought | forward | 1,010,458 | 808,773 | ||
| TOTAL FUNDS CARRIED FORWARD | 1,028,749 | 1,010,458 |
| Unrestricted | Total | ||
|---|---|---|---|
| fund | funds | ||
| Notes | 6 | ||
| FIXEDASSETS | |||
| Investments | 1,019,136 | 1,012,362 | |
| CURRENT ASSETS | |||
| Cash at bank | 10,302 | 8,786 | |
| CREDITORS | |||
| Amounts falling due within one year |
(689) | (10,690) | |
| NET CURRENT ASSETS | 9,613 | (1,904) | |
| TOTAL ASSETSLESSCURRENT | |||
| LIABILITIES | 1,028,749 | 1,010,458 | |
| NET ASSETS | 1,028,749 | 1,010,458 | |
| FUNDS | |||
| Unrestricted funds |
1,028,749 | 1,010,458 | |
| TOTAL FUNDS | 1,028,749 | 1,010,458 |
| GRANTS PAYAB | LE | |||
|---|---|---|---|---|
| 2022 | 2021 | |||
| E | E | |||
| General donations | to other charitable causes | 12,500 | 38,000 | |
| The total grants paid to institutions | during the year was as | |||
| follows: | ||||
| 2022 | 2021 | |||
| 6 | 5 | |||
| Motor Neurone | 2,000 | |||
| Samaritans | 2,000 | |||
| Wye Hops | 10,000 | |||
| Young Classical Artists Trust | 10,000 | |||
| Read Easy MenCap |
12,500 | 12,500 1,500 |
||
| 12,500 | 38,000 |
| There were no trustees' expenses paid for the yea 5 April 2021. FIXEDASSETINVESTMENTS |
r ended 5 April 2022 nor for the year ende |
|---|---|
| Listed | |
| investments | |
| F | |
| MARKET VALUE | |
| At 6April 2021 | 1,012,362 |
| Additions | 232,243 |
| Disposals | (57,080) |
| Revaluations | (168,389) |
| At 5 April 2022 | 1,019,136 |
| NET BOOK VALUE | |
| At 5 April 2022 | 1,019,136 |
| At 5 April 2021 | 1,012,362 |
| 5.4.22 | 5.4.21 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | f | ||||||||||||
| Historicai cost | (All | UK) | 318,195 | 143,032 | |||||||||
| The following | holdings | each | comprise | more | than | 5'Yo of the | market | value | of the investment | portfolio | |||
| and are considered | by | the trustees to | be individually | material. | |||||||||
| Market | |||||||||||||
| Holding | Value | 5.4.22 | 5.4.21 | ||||||||||
| 6 | 0/ | 0/ | |||||||||||
| Astrazeneca | 54,770 | 5 40'/o | 8.15'/0 | ||||||||||
| Caledonia | Invs | 53,175 | 5.24'/o | 3.93'/o | |||||||||
| Royal Dutch Shell | Transport | 50,756 | 5.01'/o | 8.41'/o | |||||||||
| M&G Equities | Investment | Fund | 69,594 | 6.86'/o | 6.87'/o | ||||||||
| Unilever | 295,651 | 29.16'/0 | 34.16'/o | ||||||||||
| JPMorgan | GBLGrowth | & INC | 51,129 | 5.04'/o | |||||||||
| LXI Rebit PLC | 53,876 | 5 31o/o | |||||||||||
| JPMorgan | GLBCore Assets LTD | 51,982 | 5.13'/o | ||||||||||
| Cost or valuation | at 5 April 2022 is represented | by: | |||||||||||
| Listed | |||||||||||||
| investment | |||||||||||||
| 6 | |||||||||||||
| Valuation in 2021 |
1,012,362 | ||||||||||||
| Valuation in 2022 |
6,774 | ||||||||||||
| 1,019,136 | |||||||||||||
| CREDITORS: | AMOUNTS FALLING DUE WITHIN | ONE YEAR | |||||||||||
| 2022 | 2021 | ||||||||||||
| 6 | 6 | ||||||||||||
| Trade creditors | 10,000 | ||||||||||||
| Other creditors | 689 | 690 | |||||||||||
| 689 | 10,690 |
| 2022 E |
2021f | |||
|---|---|---|---|---|
| INCOME AND ENDOWMENTS | ||||
| Investment income |
||||
| Dividends receivable | 25,875 | 25,165 | ||
| Deposit account interest | 847 | |||
| 26,722 | 25,165 | |||
| Total incoming resources | 26,722 | 25,165 | ||
| EXPENDITURE | ||||
| Charitable activities |
||||
| Grants to institutions | 12,500 | 38,000 | ||
| Supportcosts | ||||
| Management | ||||
| Administration fees |
960 | 240 | ||
| Accountancy fees | 360 | 400 | ||
| 1,320 | 640 | |||
| Governance costs | ||||
| Sundries | 1,331 | |||
| Independent examiner's fees |
348 | 290 | ||
| 1,679 | 290 | |||
| Total resources expended | 15,499 | 38,930 | ||
| Net income/(expenditure) | before gains | |||
| and losses | 11,223 | (13,765) | ||
| Realised recognised gains and losses | ||||
| Realised gains/(losses) | on | fixed asset | ||
| investments | 175,457 | |||
| Net income/(expenditure) | 186,680 | (13,765) |